Confusion remains about exactly how many Australian companies will be impacted by looming US pharmaceutical tariffs.

Last week Donald Trump announced that from October, the United States will impose a 100 per cent tariff on branded or patented pharmaceutical imports, unless a pharmaceutical company builds a manufacturing plant in the US.

• Guest: Elizabeth De Somer, CEO, Medicines Australia 
• Producers: Oscar Coleman and Brooke Young